China's life sciences industry has transformed into an innovation center of global significance, built upon accelerated regulatory pathways, strong policy support, and rapidly improving R&D efficiency across pharmaceuticals, medical devices, and biotechnology.

Approximately 2,390 words | 5–6 min read

For a long time, China's innovative drug story was about the journey from "me-too" to "me-better." But halfway through 2026, the narrative has shifted—valuation is no longer driven by vision, but by hard metrics: pipeline data, deal values, and enrollment speed.

KPMG's recently released 2026 China Life Sciences Sector Overview and Outlook (1) validates this transformation with data: China's life sciences industry is emerging as a globally significant innovation hub, with accelerating regulatory pathways, robust policy support, and visibly improved R&D efficiency across pharma, devices, and biotech. Digital technologies—AI, robotics, and smart manufacturing—are also reshaping the entire value chain.

Why does China's innovative drug sector deserve global recognition? This article distills key signals from the KPMG report, combined with on-the-ground market insights, to unpack the real logic behind global demand.

1. BD & M&A: From "Selling Assets" to "Selling Systems"

License-out is no longer new, but this year's shift lies in deal density and structure.

Chinese pharma and biotech out-licensing transactions have transitioned from the early "China-for-China" model to a "China-for-global" model. This means buyers no longer view Chinese assets merely as "value-for-money pipeline fillers," but are truly integrating them into global strategic planning.

The pace confirms this trend: Q1 2026 deal value has already exceeded US$60 billion, approaching half of the full-year 2025 total. This is underpinned by clear cost advantages—drug discovery costs in China are 30%–40% lower than in the US/EU, and clinical trial enrollment is 2–3 times faster. BD is becoming the primary battleground for many pipeline-driven companies.

2. Global Expansion: From Single-Asset Licensing to Full-Chain Capability Export

"Going global" previously referred mainly to license-out, but this year its scope has broadened significantly—CDMO capacity expansion overseas, internationalization of clinical development capabilities, and even some companies' early attempts at independent overseas commercialization are all advancing in parallel.

Global expansion is no longer a one-off "transactional move," but is gradually becoming part of an organization's core capabilities: Can a company design clinical protocols that meet FDA/EMA review standards? Can it manage cross-time-zone BD negotiations? All of this tests team maturity.

3. AI Drug Discovery: From Proof-of-Concept to Full-Process Integration

According to the KPMG report, by 2025 China already had over 100 AI pharmaceutical companies. AI is no longer a point solution—it now appears across nearly every stage: target identification, lead compound generation, protein prediction, preclinical optimization, clinical development and proof-of-concept, launch, and commercial execution. Integrating AI into drug R&D is no longer a choice—the gains in efficiency and shortened timelines are tangible.

For investors, evaluating an AI pharma company on algorithm stories alone is no longer enough. The key is whether it can translate "R&D efficiency" into "real clinical and commercial returns" while building a sustainable business model and economic moat.

4. Metabolic Diseases: The Second Growth Curve Beyond GLP-1

The explosive growth in weight loss and diabetes has made "metabolic diseases" one of the most crowded fields over the past two years. But differentiation is intensifying in 2026—competition for single-target GLP-1 products has become fierce, and capital is shifting toward multi-target combinations, oral small molecules, and underserved indications like MASH (metabolic dysfunction-associated steatohepatitis).

In the second half of the metabolic race, the differentiator is no longer "having a pipeline," but whether the mechanism is sufficiently differentiated and the data robust enough.

5. ADCs: China's Global Pricing Power

Antibody-drug conjugates (ADCs) are one of the brightest spots in Chinese innovative drug outbound deals.

Globally, 90% of ADC licensing transactions involve Chinese assets (3). This figure, to some extent, demonstrates that Chinese teams have built genuine technological moats in linker chemistry and payload design—not just cost advantages. Competition around differentiated targets (e.g., Claudin18.2, B7-H3) and next-generation linker technologies will be a core focus for ADC investment in the next phase.

6. CGT: An Emerging Outbound Direction Under Policy Tailwinds

Cell and gene therapy (CGT) is positioned in the report as still an emerging out-licensing direction.

Compared to ADCs and bispecific antibodies, CGT globalization is still in its early stages—but that precisely signals a window of opportunity. With growing domestic regulatory support for cell therapy products, platforms beyond CAR-T—including TCR-T, universal cell therapies, and gene-editing technologies—are moving from the "lab stage" toward "clinical value validation."

7. Small Nucleic Acids: The Underestimated Third Technology Path

Compared to the buzz around ADCs and CGT, small nucleic acid drugs (siRNA/ASO) have received relatively less attention in China, but this is changing in 2026 (4).

The demand for long-acting, low-frequency dosing in chronic disease management (e.g., cardiovascular, metabolic disorders) is making the commercial prospects of small nucleic acid drugs increasingly clear. China's growing self-sufficiency in delivery systems (e.g., GalNAc conjugation technology) is also shifting this field from "following international patents" toward "platform-based independent innovation."

8. mRNA Vaccines: Technological Repositioning in the Post-COVID Era

The COVID-19 pandemic spurred the first wave of industrialization for mRNA technology. But as the pandemic recedes, the industry faces a more fundamental question: Where does the value of the mRNA platform truly lie? The answer is shifting from infectious disease vaccines toward higher-barrier directions—tumor personalized vaccines, rare disease protein replacement therapies, and beyond.

Several early-mover platform companies in China are expanding indications to prove that mRNA is not a "pandemic-specific technology," but a sustainable foundational platform (5).

9. Autoimmune Landscape Restructuring: From "Follow-on Biosimilars" to "Differentiated Mechanisms"

The autoimmune disease space has been dominated over the past few years by biosimilars targeting mature targets like TNF-α and IL-17, leading to intense homogeneity.

The shift in 2026 is that more companies are betting on oral small molecules (e.g., TYK2 inhibitors), bispecific/multispecific antibody mechanisms, and precision stratification strategies for specific patient subtypes (3). The "landscape restructuring" in autoimmune diseases essentially reflects an industry transition from competing on regulatory approval speed to competing on mechanistic differentiation and long-term efficacy data.

10. Domestic Regulatory Trends: From "Accelerated Approval" to "Systemic Support"

With the biopharmaceutical industry established as an "emerging pillar industry," the market anticipates a systemic strengthening of full-chain policy support. This policy upgrade is expected to span R&D, capital, approval, manufacturing, application, and reimbursement. This means future policy dividends will not be limited to "faster drug approvals," but will extend to deeper institutional design—including医保 (health insurance) reimbursement, innovative drug and device centralized procurement rules, and capital market tolerance for innovative company valuations.

Despite persistent challenges—homogeneous competition, funding difficulties, and pricing misalignment—as the report notes, with strategic reinforcement from the 15th Five-Year Plan, continued optimization of the review and approval system, and the ongoing improvement of multi-tiered payment systems, the industry's structural opportunities far outweigh short-term pains.

For primary market investors, the task for 2026 is no longer to find the next "great story," but to navigate the complex interplay of these ten keywords and identify assets with truly persuasive data that can withstand market cycles.

Perhaps this is the answer that China's life sciences industry in 2026 offers to all its participants: Stories may ebb, but data will not.

References

1. https://kpmg.com/cn/zh/insights/2026/04/china-life-sciences-sector-overview-and-outlook-2026.html

2. https://mp.weixin.qq.com/s/YriJoVGbwPioMUTt6iw7Eg

3. https://mp.weixin.qq.com/s/9gxWXKtnN7jvYguBIEktZw

4. https://mp.weixin.qq.com/s/xfzyvdHQzC4aUIFa-4TmcA

5. https://mp.weixin.qq.com/s/Y7PdeENfntytg1px_Chd4Q